InvestSMART

Prelude Therapeutics (NASDAQ: PRLD) - Share Price

Current share price for PRLD : $5.490 0.11 (1.96%)+

Currency: USD ($)

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approachesto clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It with novelpayloads.

PRLD General Information +

NASDAQ Code PRLD
Industry/Sector Biotechnology
Market Cap ($M) 438
PRLD Share Price $5.490
Day High $5.610
Day Low $5.260
Last Close $5.600
PRLD Share Price Movement $0.11 ( 1.96% )
Prices as at 3:44, 2 Sep 2026
+Security prices are at best end-of-day and are indicative only.

PRLD Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
n/a n/a ($13.90) 123.23% 0.81 n/a n/a -11.07

PRLD Calendar of Events

Created Date Changed Date Event
01 May 2026 01 May 2026 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.